Moody Kate A, Iofel Samuel S, Clements Matthew B
Department of Urology, Lahey Hospital & Medical Center, 41 Mall Road, Burlington, MA, USA.
Tufts University School of Medicine, Boston, MA, USA.
Curr Urol Rep. 2024 Dec 11;26(1):21. doi: 10.1007/s11934-024-01248-y.
The purpose of this review is to highlight the health-related quality of life (HRQOL) burden of bladder cancer due to the disease itself and its treatments.
Large database studies have provided evidence that patients with bladder cancer have worse HRQOL than the general population. While transurethral resections and intravesical therapy are known to cause urinary symptoms, a large impact on HRQOL otherwise has not been demonstrated. Radical cystectomy (RC) has considerable morbidity, but after an initial adjustment period, there are favorable HRQOL outcomes. Evidence is insufficient to conclude that there are HRQOL advantages for continent versus ileal conduit urinary diversion, minimally invasive RC, or trimodal therapy. Bladder cancer and its treatment has a considerable HRQOL burden, but even among those requiring radical treatment, acceptable long term HRQOL is possible. Research on improved HRQOL assessment and translating this to personalized support are needed.
本综述旨在强调膀胱癌因其疾病本身及其治疗方法而导致的与健康相关的生活质量（HRQOL）负担。
大型数据库研究提供的证据表明，膀胱癌患者的HRQOL比一般人群更差。虽然经尿道切除术和膀胱内治疗已知会引起泌尿系统症状，但尚未证明对HRQOL有重大影响。根治性膀胱切除术（RC）有相当高的发病率，但经过初始调整期后，HRQOL结果良好。尚无足够证据得出结论认为，可控性尿流改道与回肠代膀胱尿流改道、微创RC或三联疗法相比在HRQOL方面具有优势。膀胱癌及其治疗会带来相当大的HRQOL负担，但即使在那些需要进行根治性治疗的患者中，也有可能实现可接受的长期HRQOL。需要开展关于改进HRQOL评估并将其转化为个性化支持的研究。
